PharmaCyte Biotech Inc (PMCB)

[Daphnis]

PMCB likely up-listing (NASDAQ)
1. To elect seven directors as nominated by the Board of Directors of PharmaCyte (“Board”), each to serve a one-year term;
-PMCB is doubling the number of Directors. The 7 new directors would serve a 1 year term. Interesting.

2. To approve a Certificate of Amendment to PharmaCyte’s Articles of Incorporation to increase the number of our authorized shares of common stock;
-Allowing them to raise money opportunistically and take advantage of strong capital markets or simply strong interest in their stock should be a good thing.

3. To approve PharmaCyte’s 2021 Equity Incentive Plan; and
-tbd

4. To ratify PharmaCyte’s appointment of Armanino LLP as PharmaCyte’s independent registered public accounting firm for the fiscal year ending April 30, 2022.
-The announcement will be earlier but I bet in or around a year from now the actual listing will take place. They probably need this accountant so they have one year of certified year end statements.